Anúncio
Anúncio

BNGO

BNGO logo

Bionano Genomics, Inc. Common Stock

1.57
USD
Patrocinado
-0.03
-1.56%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

1.60

+0.03
+1.59%

Relatórios de Lucros BNGO

Rácio de surpresa positiva

BNGO separação 10 de 29 últimas estimativas.

34%

Próximo Relatório

Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$7.94M
/
-$1.43
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+7.81%
/
-10.06%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-2.71%
/
-90.97%

Bionano Genomics, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, BNGO reported earnings of -1.59 USD per share (EPS) for Q3 25, beating the estimate of -1.94 USD, resulting in a 18.39% surprise. Revenue reached 7.37 milhão, compared to an expected 7.01 milhão, with a 5.12% difference. The market reacted with a +3.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -1.43 USD, with revenue projected to reach 7.94 milhão USD, implying an diminuir of -10.06% EPS, and aumentar of 7.81% in Revenue from the last quarter.
FAQ
For Q3 2025, Bionano Genomics, Inc. Common Stock reported EPS of -$1.59, beating estimates by 18.39%, and revenue of $7.37M, 5.12% above expectations.
The stock price moved up 3.4%, changed from $1.47 before the earnings release to $1.52 the day after.
The next earning report is scheduled for 30 de mar. de 2026.
Based on 5 analistas, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$1.43 and revenue of $7.94M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio